Anika Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Anika Therapeutics Inc ANIK.OQ reported a quarterly adjusted loss of $1.50​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-4.30. The mean expectation of two analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -51 cents to -8 cents per share.

• Revenue fell 28.8% to $30.60 million from a year ago; analysts expected $29.00 million.

• Anika Therapeutics Inc's reported EPS for the quarter was a loss of $1.50​.

• The company reported a quarterly loss of $21.87 million.

• Anika Therapeutics Inc shares had risen by 2.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1,866.7% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "strong buy"

Wall Street's median 12-month price target for Anika Therapeutics Inc is $26.50

This summary was machine generated from LSEG data March 12 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)